EYW Stock Overview

Develops and markets in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. More details

EYW fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	1/6
Past Performance	4/6
Financial Health	6/6
Dividends	3/6

Rewards

Trading at 27% below our estimate of its fair value

Revenue is forecast to grow 5.14% per year

Earnings grew by 8.5% over the past year

Risk Analysis

Earnings are forecast to decline by an average of 0.1% per year for the next 3 years

Shares are highly illiquid

My Notes

Capture your thoughts, links and company narrative

bioMérieux S.A. Competitors

Carl Zeiss Meditec

XTRA:AFX

€4.0b

Siemens Healthineers

XTRA:SHL

€58.3b

Eckert & Ziegler

XTRA:EUZ

€929.3m

Drägerwerk KGaA

XTRA:DRW3

€807.0m

Price History & Performance

Summary of share price highs, lows and changes for bioMérieux
Historical stock prices
Current Share Price	€8.65
52 Week High	€9.10
52 Week Low	€8.05
Beta	0.056
1 Month Change	0%
3 Month Change	-3.89%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0.58%

Recent updates

Shareholder Returns

	EYW	DE Medical Equipment	DE Market
7D	0%	-3.3%	-2.0%
1Y	n/a	-8.5%	6.9%

Return vs Industry: Insufficient data to determine how EYW performed against the German Medical Equipment industry.

Return vs Market: Insufficient data to determine how EYW performed against the German Market.

Price Volatility

Is EYW's price volatile compared to industry and market?
EYW volatility
EYW Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	6.7%
Market Average Movement	4.9%
10% most volatile stocks in DE Market	11.3%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: EYW has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine EYW's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
1963	12,232	Alexandre Merieux	www.biomerieux.com

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories.

bioMérieux S.A. Fundamentals Summary

How do bioMérieux's earnings and revenue compare to its market cap?
EYW fundamental statistics
Market cap	€10.75b
Earnings (TTM)	€552.00m
Revenue (TTM)	€3.46b

19.5x

P/E Ratio

3.1x

P/S Ratio

Is EYW overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EYW income statement (TTM)
Revenue	€3.46b
Cost of Revenue	€1.48b
Gross Profit	€1.98b
Other Expenses	€1.43b
Earnings	€552.00m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

Oct 26, 2022

Earnings per share (EPS)	4.66
Gross Margin	57.26%
Net Profit Margin	15.95%
Debt/Equity Ratio	13.4%

How did EYW perform over the long term?

See historical performance and comparison

Dividends

0.9%

Current Dividend Yield

18%

Payout Ratio

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2022/09/07 14:44
End of Day Share Price	2022/06/10 00:00
Earnings	2022/06/30
Annual Earnings	2021/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

bioMérieux S.A. is covered by 34 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Armelle Moulin	AlphaValue
Gaurav Jain	Barclays
Samuel England	Berenberg